I saw a patient last week whose journey through IVF mirrored the path of many founders I’ve had the fortune—or misfortune, depending on the day—to back in my angel investing career. She was a resilient woman, full of hope yet acutely aware of the uncertainties she faced. We discussed the risks, the potential for failure, and the emotional investment required. As we talked, I couldn’t help but draw parallels to the startup world. Both are fraught with risks, demand immense patience, and require a deep personal commitment. The lessons I’ve learned from my patients have profoundly shaped how I assess risks in startups.
In both domains, risk is a constant companion. In my clinic, every IVF cycle is a calculated risk, with no guarantees. Similarly, every investment in a startup is a gamble, albeit an educated one. Just as my patients are aware of the odds, founders must also understand the precariousness of their ventures. But here’s the crux: understanding risk isn’t about fearing it; it’s about embracing it with eyes wide open.
I’ve often encountered founders who seem to view risk as a mere checkbox on their investor pitch, something to gloss over with a few buzzwords. But in reality, risk is the bedrock of innovation. Just as my patients must grapple with the possibility of an unsuccessful cycle, founders must acknowledge that failure is a real possibility. Yet, this acknowledgment should not paralyze them. Rather, it should motivate them to plan meticulously and execute with precision.
In my experience, the most successful founders are those who, like my patients, are intimately acquainted with their vulnerabilities. They don’t shy away from discussing potential pitfalls; instead, they confront them head-on. This brings me to a critical point: transparency. In the same way I encourage patients to be candid about their fears and expectations, I urge founders to be transparent with their investors. There’s a certain strength in vulnerability. When a founder openly acknowledges risks and outlines strategies to mitigate them, it builds trust—a currency more valuable than capital.
This isn’t just theoretical musing. I’ve seen it play out in real scenarios. I recall a founder I backed who was developing an AI-driven healthtech solution. During our discussions, he laid out, with startling clarity, the technological hurdles his team faced and the regulatory challenges that loomed. He didn’t sugarcoat the difficulties; he didn’t promise seamless execution. Instead, he demonstrated a deep understanding of the landscape and a well-thought-out plan to navigate it. That transparency was a key factor in my decision to invest in his venture.
In the realm of startups, much like in IVF, patience is a virtue. The gestation period for an idea to become a viable product can be long and fraught with setbacks. This is something my patients know all too well. An IVF cycle isn’t a sprint; it’s a marathon, requiring emotional endurance and unwavering resolve. Similarly, founders must be prepared for an arduous journey. I’ve written before about the importance of trusting the process, whether in IVF or in startups. Both require a long-term vision and the ability to weather storms without losing sight of the ultimate goal.
A common mistake I see among founders is an obsession with short-term metrics. They chase immediate validation while neglecting the foundational work that ensures long-term success. This is akin to a patient fixating on a single cycle’s outcome rather than focusing on the overall treatment plan. In both cases, the myopic view can lead to burnout and disillusionment. Founders, much like my patients, need to balance hope with realism. They must celebrate small victories but remain cognizant of the larger picture.
Another lesson from my medical practice that applies to investing is the importance of adaptability. In the clinic, each patient presents a unique set of challenges that often require tailoring the approach. Similarly, startups operate in dynamic environments where flexibility can be a game-changer. I’ve seen startups that pivot decisively in response to market feedback outperform those rigidly adhering to their initial plans. In both domains, the ability to adapt is not just an advantage; it’s a necessity.
But perhaps the most profound lesson my patients have taught me is the power of resilience. The fortitude I witness in couples facing repeated IVF cycles is nothing short of inspiring. It’s a reminder that failure is not a verdict but a stepping stone. This resilience is equally critical for founders. I’ve often said that every startup founder should learn from IVF patients’ emotional fortitude. The capacity to persist in the face of setbacks can be the differentiator between a startup that falters and one that ultimately triumphs.
In conclusion, the intersection of my work in IVF and my role as an angel investor offers a unique vantage point on risk. Both domains are arenas of uncertainty that demand courage, transparency, patience, adaptability, and resilience. My patients’ stories are a constant reminder that while risk is inherent in any venture, it is also the catalyst for growth and innovation. As I continue to navigate these two worlds, I remain committed to embracing risk—not as a deterrent, but as an integral part of the journey toward meaningful impact.